相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes
Juan A. Marin-Jimenez et al.
FRONTIERS IN IMMUNOLOGY (2021)
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
Sarah J. Hartman et al.
FRONTIERS IN ONCOLOGY (2021)
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Lucy C. Riches et al.
MOLECULAR CANCER THERAPEUTICS (2020)
DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia
Michael Carr et al.
FRONTIERS IN ONCOLOGY (2020)
Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells
Clara Dobler et al.
CELLS (2020)
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Charlie Gourley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC
Adwitiya Kar et al.
ENDOCRINE-RELATED CANCER (2019)
ATM in DNA repair in cancer
Mei Hua Jin et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Statistical determination of synergy based on Bliss definition of drugs independence
Eugene Demidenko et al.
PLOS ONE (2019)
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
Peter J. Klauck et al.
BMC CANCER (2018)
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)
Kurt G. Pike et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Evaluation of Drug Combination Effect Using a Bliss Independence Dose-Response Surface Model
Qin Liu et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2018)
Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status
Hind Hafsi et al.
FRONTIERS IN ONCOLOGY (2018)
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models
Anna Capasso et al.
ANTI-CANCER DRUGS (2018)
The Tumor Suppressor MIG6 Controls Mitotic Progression and the G2/M DNA Damage Checkpoint by Stabilizing the WEE1 Kinase
Mari Sasaki et al.
CELL REPORTS (2018)
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry
Gemma N. Jones et al.
BRITISH JOURNAL OF CANCER (2018)
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy
Justin Greene et al.
ONCOTARGET (2017)
Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer
Anastasia A. Ionkina et al.
FRONTIERS IN ONCOLOGY (2017)
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
Kevin S. Quackenbush et al.
ONCOTARGET (2016)
ATM and ATR as therapeutic targets in cancer
Anika Maria Weber et al.
PHARMACOLOGY & THERAPEUTICS (2015)
ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays
Camilo Guzman et al.
PLOS ONE (2014)
Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer
Todd M. Pitts et al.
PLOS ONE (2014)
CHK2 kinase in the DNA damage response and beyond
Laura Zannini et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2014)
ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation
Laura Biddlestone-Thorpe et al.
CLINICAL CANCER RESEARCH (2013)
Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer
Michael A. Batey et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer
Erica L. Bradshaw-Pierce et al.
PLOS ONE (2013)
Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells
David Davidson et al.
INVESTIGATIONAL NEW DRUGS (2012)
The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models
Sara A. Flanigan et al.
CLINICAL CANCER RESEARCH (2010)
Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin
JX Wu et al.
MOLECULAR PHARMACOLOGY (2002)
分享论文
